Micafungin Wockhardt Uk (Micafungin)

• Micafungin is an echinocandin antifungal indicated for several serious Candida infections.
• Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in adult and pediatric patients.
• Candida esophagitis: eradication of esophageal Candida infection causing dysphagia and pain.
• Febrile neutropenia: empirical therapy for suspected fungal infection in neutropenic patients with fever.
• Prophylaxis of Candida infections: prevention of invasive candidiasis in high‑risk patients such as those undergoing hematopoietic stem cell transplantation.

• Micafungin exerts its antifungal activity by selectively inhibiting the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesis of β‑(1,3)‑D‑glucan, a critical structural component of the fungal cell wall. Disruption of β‑(1,3)‑D‑glucan formation weakens the cell wall, leading to osmotic instability and cell lysis, while human cells lacking this polymer are unaffected.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature during or after infusion.
• Nausea: mild to moderate feeling of stomach upset.
• Headache: mild headache occurring during treatment.
• Elevated liver enzymes: mild increase in ALT or AST levels.
• Rash: mild skin erythema or itching.
• Infusion-related reactions: flushing, chills, or mild hypotension.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury with jaundice or elevated bilirubin.
• Anaphylaxis: life‑threatening allergic reaction with respiratory distress.
• Stevens‑Johnson syndrome: severe skin and mucosal blistering.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Renal impairment: acute kidney injury with rising creatinine.
• Sepsis-like syndrome: systemic inflammatory response.

• When using Micafungin, clinicians should observe several precautionary measures to ensure patient safety.
• Monitor liver function: check baseline and periodic ALT/AST levels during therapy.
• Assess for hypersensitivity: discontinue if signs of severe allergic reaction appear.
• Use with caution in hepatic impairment: dose adjustment may be required in patients with pre‑existing liver disease.
• Renal function consideration: monitor renal parameters, especially in patients with existing kidney dysfunction.
• Drug interaction vigilance: review concomitant medications that may affect micafungin metabolism, such as strong CYP3A4 inducers.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; understanding the interaction level helps manage risk.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may significantly reduce micafungin exposure.
• Co‑administration with other echinocandins: increased risk of hepatotoxicity.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin plasma levels.
• Warfarin: potential alteration of anticoagulant effect, monitor INR.
• Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustment due to metabolic pathways.